ACE2 and COVID-19: In contrast to the findings with IgM, anti-ACE2 IgG autoantibodies were not enriched in severe disease, as found in 12/66 (18%) patients with severe COVID-19 (WHO 6–8) and 6/52 (11.5%) patients with moderate (WHO 3–5) disease (P = 0.44 by Fisher’s exact test).